{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:53:31Z","timestamp":1781535211520,"version":"3.54.5"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201853, 82504941"],"award-info":[{"award-number":["82201853, 82504941"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Globally, breast cancer is the most common malignancy in women. Despite treatment advances, 20\u201330% of early-stage patients progress to advanced disease, which remains largely incurable with a 5-year survival rate of only ~20%. Chemotherapy, the current mainstay, has reached a therapeutic plateau, with limited efficacy and potential pro-metastatic effects. Anti-angiogenic agents targeting VEGF\/VEGFR2 (e.g., bevacizumab, TKIs) are used clinically, but their benefit in advanced breast cancer is controversial: progression-free survival (PFS) gains are inconsistent, overall survival (OS) benefits are unclear, and resistance with class-specific toxicities (e.g., hypertension) is common. Furthermore, comparative efficacy across drug classes and optimal patient selection remain undefined. These unresolved issues highlight the urgent need for a comprehensive synthesis to guide clinical decisions and future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic search of PubMed\/Web of Science (up to July 16, 2025) identified 29 phase II\/III RCTs (N = 8,480) comparing angiogenesis inhibitors + chemotherapy vs. chemotherapy alone (\u00b1 placebo) in advanced breast cancer. Outcomes included PFS, OS, objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), and safety. Two independent reviewers performed screening, extraction, and quality assessment. Pooled HRs (95% CI) for PFS\/OS; ORs for binary outcomes. Random-effects model used if I\u00b2 \u2265 50%; prespecified subgroup\/sensitivity analyses explored heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This meta-analysis (29 RCTs, N = 11,068) showed that adding angiogenesis inhibitors in advanced breast cancer significantly improved PFS (HR 0.75), ORR, CBR, and DCR (all P&amp;lt;0.001), but not OS (HR 0.95, P = 0.171). PFS benefit varied by subtype: mAbs (e.g., bevacizumab) outperformed TKIs in TNBC (HR 0.59 vs. 0.75); TKIs trended better in HR+ disease (HR 0.67). Benefit was consistent across metastasis patterns but greater in patients without bone metastasis. Safety risks increased significantly, including hypertension (OR 4.59), thrombocytopenia (OR 4.54), proteinuria (OR 2.38), hand-foot syndrome (OR 2.14), and diarrhea (OR 1.97).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis (29 RCTs) finds that adding angiogenesis inhibitors to chemotherapy significantly improves PFS and response in advanced breast cancer\u2014especially in TNBC with mAbs and HR+ disease with TKIs\u2014but not OS. Benefit is independent of visceral metastasis but reduced in bone metastases. Increased toxicities (hypertension, proteinuria, hand-foot syndrome, diarrhea) warrant proactive management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1820120","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:07:29Z","timestamp":1780636049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiangzhuo","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"National Clinical Key Specialty (General Surgery)\/National Clinical Research Center for Digestive Diseases\/Sichuan Clinical Research Center For Digestive Diseases","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/bcr2573","article-title":"Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone","author":"Rivera","year":"2010","journal-title":"Breast Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118449","article-title":"Indole hybrids: emerging therapeutic candidates for breast cancer (2023-2025)","volume":"303","author":"Huang","year":"2026","journal-title":"Eur J Med Chem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/s41467-022-33598-x","article-title":"Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer","volume":"13","author":"Monteran","year":"2022","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12935-024-03401-6","article-title":"Muscone abrogates breast cancer progression through tumor angiogenic suppression via VEGF\/PI3K\/Akt\/MAPK signaling pathways","volume":"24","author":"Wang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"699478","DOI":"10.2139\/ssrn.3829636","article-title":"\u03b3\u03b4T Cell-IL17A-Neutrophil\" axis drives immunosuppression and confers breast cancer resistance to high-dose anti-VEGFR2 therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.125.042896","article-title":"Major adverse cardiovascular events in angiogenesis inhibitor-based cancer therapy: a systematic review and meta-analysis","volume":"14","author":"Tao","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0515","article-title":"Research progress in tumor angiogenesis and drug resistance in breast cancer","volume":"21","author":"Mou","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-024-09913-z","article-title":"Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism","volume":"27","author":"Yang","year":"2024","journal-title":"Angiogenesis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.03.042","article-title":"Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro","volume":"369","author":"Shamshiripour","year":"2024","journal-title":"J Control Release"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120645","article-title":"Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles","volume":"269","author":"Shashni","year":"2021","journal-title":"Biomaterials"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125788","article-title":"Vicious-cycle-breaking antiangiogenic nano-delivery systems potentiate and simplify the tumor vascular normalization strategy","volume":"681","author":"Qi","year":"2025","journal-title":"Int J Pharm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120670","article-title":"Chaihu Longgu Muli Decoction attenuates chronic stress-induced endothelial dysfunction and potentiates chemotherapy in breast cancer by inhibiting cAMP\/PKA\/CREB1 mediated glycolysis","volume":"355","author":"Li","year":"2026","journal-title":"J Ethnopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111607","article-title":"Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy","volume":"139","author":"Liu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117101","article-title":"Therapeutic potential of HDAC inhibitors in a xenograft model of cancers: a special focus on breast cancer","volume":"240","author":"Rubin","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e009658","DOI":"10.1136\/jitc-2024-009658","article-title":"Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events","volume":"12","author":"Rubin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.semcancer.2022.03.003","article-title":"Promalignant effects of antiangiogenics in the tumor microenvironment","volume":"86","author":"Peix","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00523-6","article-title":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07167-9","article-title":"A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer","volume":"204","author":"Mayer","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13058-020-01258-x","article-title":"TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2\/3 hormone receptor-positive and HER2-negative breast cancer","volume":"22","author":"Vaklavas","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70037-7","article-title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"12","author":"Martin","year":"2011","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.7912","article-title":"AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.3391","article-title":"Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer","volume":"31","author":"Crown","year":"2013","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.005","article-title":"A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer","volume":"49","author":"Gradishar","year":"2013","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.11.003","article-title":"Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: a phase 2 randomized study","volume":"24","author":"Di\u00e9ras","year":"2015","journal-title":"Breast"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07417-4","article-title":"A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2\/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)","volume":"207","author":"Mezzanotte-Sharpe","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.2388","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole\/fulvestrant and avastin (LEA) study","volume":"33","author":"Mart\u00edn","year":"2015","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.66.1595","article-title":"Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance)","volume":"34","author":"Dickler","year":"2016","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.5298","article-title":"Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502\/NCCTG N063H (Alliance)","volume":"33","author":"Rugo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv263","article-title":"Randomized, phase II, placebo-controlled trial of onartuzumab and\/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer","volume":"26","author":"Di\u00e9ras","year":"2015","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.clbc.2017.05.006","article-title":"RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer","volume":"17","author":"Baselga","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70439-5","article-title":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12885-017-3492-1","article-title":"A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)","volume":"17","author":"Decker","year":"2017","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.clbc.2016.07.005","article-title":"Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II study","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","volume":"70","author":"Miles","year":"2017","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000512200","article-title":"Carboplatin-cyclophosphamide or paclitaxel without or with bevacizumab as first-line treatment for metastatic triple-negative breast cancer (BOOG 2013-01)","volume":"16","author":"van Rossum","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41523-022-00462-6","article-title":"Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first\/second-line treatment: the NAN trial","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00579-x","article-title":"Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial","volume":"25","author":"Fan","year":"2024","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101563","article-title":"A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"ESMO Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.7771","article-title":"Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer","volume":"30","author":"Baselga","year":"2012","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.02.002","article-title":"Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: final results of the randomized, double-blind, placebo-controlled phase II MADONNA study","volume":"45","author":"Mavratzas","year":"2019","journal-title":"Breast"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102193","article-title":"Neoadjuvant anlotinib\/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): phase 2 trial","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.04.006","article-title":"Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-022-01763-8","article-title":"DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients","volume":"27","author":"Vasiyani","year":"2022","journal-title":"Apoptosis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1718894","DOI":"10.3389\/fimmu.2025.1718894","article-title":"Brake\" and \"accelerator\": revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy","volume":"16","author":"Wei","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000538375","article-title":"Onco-hypertension in patients with kidney disease","volume":"57","author":"Pandey","year":"2024","journal-title":"Am J Nephrol"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1901329","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1820120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:07:01Z","timestamp":1781532421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1820120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1820120"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1820120","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1820120"}}